

(43) International Publication Date
19 October 2017 (19.10.2017)



(10) International Publication Number
WO 2017/180913 A2

(1) **International Patent Classification:**
C07K 16/08 (2006.01)

(2) **International Application Number:**
PCT/US2017/027488

(22) **International Filing Date:**
13 April 2017 (13.04.2017)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**

62/322,036	13 April 2016 (13.04.2016)	US
62/331,191	3 May 2016 (03.05.2016)	US
62/412,187	24 October 2016 (24.10.2016)	US
EP17305298.6	17 March 2017 (17.03.2017)	EP

(71) **Applicant:** SANOFI [FR/FR]; 54, Rue la Boetie, 75008 Paris (FR).

(72) **Inventor; and**

(71) **Applicant (for US only):** YANG, Zhi-Yong [US/US]; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-505A, Bridgewater, NJ 08807 (US).

(72) **Inventors:** NABEL, Gary, J.; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-505A, Bridgewater, NJ 08807 (US). WU, Lan; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-505A, Bridgewater, NJ 08807 (US). SEUNG, Edward; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-505A, Bridgewater, NJ 08807 (US). WEI, Ronnie; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-505A, Bridgewater, NJ 08807 (US). BENINGA, Jochen; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt Am Main (DE). RAO, Ercole; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt Am Main (DE). LEUSCHNER, Wulf Dirk; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt Am Main (DE). BEIL, Christian; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt Am Main (DE). CORVEY, Carsten; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt Am Main (DE).

(74) **Agents:** JONES, Kevin et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— of inventorship (Rule 4.17(iv))

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

[Continued on next page]

(54) Title: TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS



(57) Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

WO 2017/180913 A2



— with sequence listing part of description (Rule 5.2(a))